GSK has signed an agreement with Syndivia, a biotechnology company specializing in next-generation antibody-drug conjugates (ADCs), to acquire exclusive worldwide rights to develop and commercialize a preclinical ADC for metastatic castration-resistant prostate cancer (mCRPC). The deal strengthens GSK’s expanding oncology pipeline and could deliver a novel targeted therapy for a patient population with few effective options.
The ADC leverages Syndivia’s GeminiMab conjugation technology to enhance tumor-targeting precision and safety. Preclinical data show potent anti-tumor activity and favorable tolerability, suggesting best-in-class potential. The therapy aims to offer a more accessible, targeted treatment for patients with mCRPC, who currently face low five-year survival rates and limited access to effective therapies.
Under the agreement, Syndivia will receive an upfront payment and milestone-based compensation up to £268 million, plus royalties on future sales. GSK will take over development, manufacturing, and commercialization responsibilities.
KEY QUOTES
“Prostate cancer represents a significant health burden and an emerging area of growth for GSK, where targeted therapies are urgently needed in metastatic castration-resistant settings. The addition of this ADC builds on GSK’s growing portfolio and strengths in tumour-targeted technologies, including GSK’227, our B7-H3-targeting ADC.”
Hesham Abdullah, Senior Vice President, Global Head Oncology R&D, GSK
“We are proud that GSK will advance this programme on a global scale. This agreement underscores the value of our GeminiMab ADC platform and the opportunity to bring a promising new therapy to patients with pressing unmet medical needs.”
Sasha Koniev, Chief Executive Officer, Syndivia
